[Tree] Gerresheimer's revenue growth from weight-loss drug deals, pharma industry's Q4 results, public interest in GLP-1 drugs

Version 0.19 (2024-07-15 02:52:49.714000)

updates: Integration of AI analysis of Reddit discussions about GLP-1 drugs

  • ➔
  • ➔
  • ➔
  • ➔
  • ➔
Version 0.18 (2024-06-23 18:54:07.467000)

updates: Integration of information about Eli Lilly and Novo Nordisk dominating the weight loss therapy market

  • ➔
  • ➔
  • ➔
  • ➔
Version 0.17 (2024-04-08 04:19:23.041000)

updates: Integration of pharma industry's Q4 results

  • ➔
  • ➔
  • ➔
Version 0.16 (2024-03-29 06:20:01.023000)

updates: Gerresheimer's revenue growth from weight-loss drug deals

  • ➔
  • ➔
Version 0.15 (2024-03-08 20:20:05.424000)

updates: FDA approval of Wegovy for cardiovascular risk reduction

  • ➔
  • ➔
  • ➔
Version 0.14 (2024-02-27 16:22:56.321000)

updates: Competition between Novo Nordisk and Zealand Pharma

  • ➔
  • ➔
Version 0.13 (2024-02-27 13:17:34.920000)

updates: The new information provides insights into the impact of GLP-1 drugs on the US economy and the challenges of obtaining these drugs for some Americans

  • ➔
  • ➔
  • ➔
Version 0.12 (2024-02-27 12:17:41.463000)

updates: The potential impact of weight loss drugs on the US economy

  • ➔
  • ➔
Version 0.11 (2024-02-23 17:21:05.948000)

updates: The success of Novo Nordisk's Ozempic and Eli Lilly's Zepbound has significantly increased the market value of both companies

  • ➔
  • ➔
Version 0.1 (2024-02-23 16:19:03.864000)

updates: The potential economic impact of weight loss drugs

  • ➔
  • ➔
Version 0.09 (2024-02-23 16:16:17.162000)

updates: The potential impact of weight loss drugs on the US economy

  • ➔
  • ➔
Version 0.08 (2024-02-23 15:19:47.290000)

updates: The potential economic impact of weight loss drugs

  • ➔
Version 0.07 (2024-02-23 08:19:25.864000)

updates: The widespread use of weight-loss drugs in the US could increase gross domestic product (GDP) by 1% in the coming years, according to Goldman Sachs. The market for weight-loss drugs is predicted to reach $100 billion a year by the end of the decade. The drugs, called GLP-1 agonists, are being pursued by several companies, including Novo Nordisk and Eli Lilly. Goldman Sachs estimates that the use of GLP-1s could increase by 10 to 70 million consumers by 2028. The brokerage also suggests that the current wave of healthcare innovation, combined with the use of GLP-1s, could raise US GDP by 1.3% in the coming years.

  • ➔
Version 0.06 (2024-02-23 08:16:45.236000)

updates: The potential economic impact of weight loss drugs

  • ➔
Version 0.05 (2024-02-22 20:19:24.244000)

updates: The potential impact of weight loss drugs on the US economy

  • ➔
Version 0.04 (2024-02-22 18:18:16.964000)

updates: The widespread use of weight-loss drugs in the United States could boost gross domestic product (GDP) by 1% in the coming years, according to Goldman Sachs. The market for weight-loss drugs is predicted to reach $100 billion a year by the end of the decade. Novo Nordisk and Eli Lilly are leading the race in producing weight-loss drugs. The use of GLP-1 agonists, a class of weight-loss drugs, could increase by 10 to 70 million consumers by 2028. Goldman Sachs estimates that weight-loss drugs could increase U.S. GDP by 0.4% with 30 million users and up to 1% with 60 million users. The current wave of healthcare innovation, including AI-powered drug discovery and GLP-1s, could raise U.S. GDP by 1.3% in the coming years, equivalent to $360 billion per year. The effects are expected to be larger in the U.S. than in other countries due to better health outcomes in other developed markets.

  • ➔
  • ➔
Version 0.03 (2024-02-22 17:16:53.392000)

updates: The potential impact of weight loss drugs on the US economy

  • ➔
Version 0.02 (2024-01-11 11:25:42.353000)

updates: New information about Eli Lilly's approval for Zepbound

  • ➔
Version 0.01 (2023-12-03 05:43:14.597000)

updates: Eli Lilly receives FDA approval for Jaypirca cd4e5614

  • ➔
Version 0.0 (2023-12-02 05:59:15.888000)

updates:

  • ➔
  • ➔